Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.
Salmeterol was granted FDA approval on 4 February 1994.
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
Urinary Concentration After Salmeterol
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 24
- Registration Number
- NCT06657547
- Locations
- 🇩🇰
August Krogh Building, Copenhagen, Denmark
Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.
- Conditions
- Healthy
- Interventions
- Drug: Placebo + placebo
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 36
- Registration Number
- NCT06654986
- Locations
- 🇩🇰
August Krogh Building, Copenhagen, Denmark
Salmeterol Effect on Exercise Performance
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 36
- Registration Number
- NCT06655012
- Locations
- 🇩🇰
August Krogh Building, Copenhagen, Denmark
ANTES B+ Clinical Trial
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30DDrug: BrimicaDrug: UlunarDrug: XoternaDrug: LaventairDrug: YanimoDrug: BroncoralDrug: OxisDrug: FormatrisDrug: StriverdiDrug: BeglanDrug: BetamicanDrug: InaspirDrug: SoltelDrug: BretarisDrug: SeebriDrug: TovanorDrug: EnurevDrug: TavulusDrug: SirkavaDrug: BraltusDrug: GregalDrug: Rolufta
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Fundacio Privada Mon Clinic Barcelona
- Target Recruit Count
- 1028
- Registration Number
- NCT06282861
- Locations
- 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
- Conditions
- Asthma
- Interventions
- Drug: Placebo to QVM149Drug: Run-In MedicationDrug: Rescue MedicationDevice: Concept 1 DeviceDevice: Girohaler
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 304
- Registration Number
- NCT05776927
Replication of the POET-COPD Trial in Healthcare Claims Data
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 8716
- Registration Number
- NCT05083429
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 24
- Registration Number
- NCT04503460
- Locations
- 🇬🇧
St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 4
- Registration Number
- NCT04195867
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: YCC capsuleDrug: BL capsule
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Henan University of Traditional Chinese Medicine
- Target Recruit Count
- 240
- Registration Number
- NCT03745261
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China
Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT03461627
- Locations
- 🇨🇳
The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.